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Abstract
Background: Prostate cancer is the second most common diagnosed cancer in men. Due to the low specificity of
current diagnosis methods for detecting prostate cancer, identification of new biomarkers is highly desirable. The
study was conducted to determine the clinical utility of the prostate cancer gene 3 (PCA3) assay to predict
biopsy-detected cancers in Chinese men.
Methods: The study included men who had a biopsy at The Affiliated Sixth People’s Hospital of Shanghai Jiao
Tong University from January 2013 to December 2013. Formalin-fixed, paraffin-embedded tissue blocks were used
to test PCA3 and prostate-specific antigen (PSA) mRNA. The diagnostic accuracy of the PCA3 score for predicting
a positive biopsy outcome was studied using sensitivity and specificity, and it was compared with PSA.
Results: The probability of a positive biopsy increased with increasing PCA3 scores. The mean PCA3 score was
significantly higher in men with prostate cancer (198.03, 95 % confidence interval [CI] 74.79–321.27) vs benign
prostatic hyperplasia (BPH) (84.31, 95 % CI 6.47–162.15, P < 0.01). The PCA3 score (cutoff 35) had a sensitivity of
85.7 % and specificity of 62.5 %. Receiver operating characteristic analysis showed higher areas under the ROC
curve for the PCA3 score vs PSA, but without statistical significance.
Conclusions: Increased PCA3 in biopsy tissue correlated with prostate cancer and the PCA3 assay may improve
the diagnosis efficacy as the PCA3 score being independent of PSA level. The diagnostic significance of urinary
PCA3 testing should be explored in future study to determine the prediction value in guiding biopsy decision
as the clinical relevance of current study was limited for PCA3 testing based on biopsy tissue in a limited number
of Chinese men.
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Background
Prostate cancer is the second most common diagnosed
cancer and the sixth leading cause of cancer deaths in
men, accounting for 14 % of total new cancer cases [1].
Prostate cancer diagnosis primarily relies on prostate-
specific antigen (PSA) and digital rectal examination
(DRE) outcome. The presence of an abnormal DRE or
an elevated PSA level is associated with increased risk of
prostate cancer, which is followed by a biopsy [2]. The
prostate cancer detection rate has greatly increased since
the discovery of PSA and widespread PSA testing [3, 4].
Due to the low specificity of PSA, only 25–40 % of pa-
tients with a PSA of 2–10 ng/ml are diagnosed with pros-
tate cancer on biopsy, resulting in a substantial number of
unnecessary biopsies [5, 6]. Many patients experience
pain, discomfort and anxiety following a biopsy, and un-
necessary biopsies may lead to complications [7–9]. The
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identification of biomarkers capable of increasing the
probability of a positive biopsy is highly desirable.
Recently the prostate cancer gene 3 (PCA3) has shown
promise in identifying men at high probability of a positive
biopsy and in guiding repeat biopsy decisions [10–15].
PCA3, which has been measured in urine in men at risk
of prostate cancer, is over-expressed in prostate cancer
cells compared with benign prostatic tissues [16]. Elevated
PCA3 scores have been associated with a positive biopsy
outcome [11], and the performance of PCA3 screening is
maintained through repeat biopsies [10, 17]. In addition,
PCA3 scores may be correlated with the tumor indexes of
prostate cancer, such as tumor volume and Gleason
score [18, 19].
Unfortunately, limited studies on the application of
PCA3 scores in prostate cancer detection in the Chinese
population are available in the literature [20]. Chinese
men differ significantly from the Western population
genetically. The clinical applicability of PCA3 scores in
Chinese men should be investigated thoroughly. There
was a high variability in cancer detection rates even
among Asian populations, and Chinese-specific data is
necessary to provide adequate information in counseling
Chinese men who would consider prostate biopsy for
suspected prostate cancer. Hence, the prostate biopsy
database was set up in Department of Pathology, Sixth
People’s Hospital affiliated to Shanghai Jiaotong Univer-
sity. The objective of the present study was to examine
the performance characteristics of the PCA3 score in pre-
dicting biopsy-detected prostate cancer in the Chinese
population. We also compared the performance of the
PCA3 assay to that of PSA.
Methods
Study design
The study included men who had a biopsy at The
Affiliated Sixth People’s Hospital of Shanghai Jiao Tong
University from January 2013 to December 2013, exclud-
ing men with medical therapy known to affect PSA or
invasive treatment for benign prostatic hyperplasia (BPH).
The study was reviewed and approved by the Ethics
Committee of The Affiliated Sixth People’s Hospital of
Shanghai Jiao Tong University. All subjects received a
detailed explanation of the study and written informed
consent was obtained from all participants.
The histological slides were blinded and evaluated
independently of the results of the other assays by two
experienced pathologists. If the diagnosis differed between
two pathologists, histological slides were reviewed again
and a consensus diagnosis was obtained.
Specimen collection and PCA3 assay procedure
Prostate cancer and BPH specimens were obtained
from formalin-fixed, paraffin-embedded tissue blocks.
We examined a series of 136 primary specimens collected
by needle biopsy at the hospital. After adding 800 μl
dimethylbenzene, tissue sections were incubated at 65 °C
for 10 min to remove the paraffin. When tissue was to be
manually dissected or scraped, the sections were immedi-
ately transferred to a microcentrifuge tube. The tube was
centrifuged at 13,000 rpm for 3 min and the supernatant
was sucked up. Then 800 μl 100 % ethanol was added and
centrifuged again at 13,000 rpm for 5 min with the super-
natant discarded. Then 800 μl 50 % ethanol was added
and centrifuged at 14,000 rpm for 10 min with the super-
natant discarded. Then 500 μL lysis mixture and pro-
teinase K 5 μL were added to the centrifuge tube and
incubated at 65 °C for 3 h. The sample tube was shaken at
1 h intervals during the incubation.
These samples after incubation were used for the
detection of PCA3 and PSA mRNA according to the
manufacturer’s instructions. The detection was based on
branched DNA (bDNA) technology (DiaCarta, CA, USA),
which is a sandwich nucleic acid hybridization procedure
for the direct quantitation without RNA purification or
reverse transcription polymerase chain reaction. The
capture plate containing sample and bifunctional oligo-
nucleotide probe sets was read on the Kodia QuantiVirus®
Luminometer System by the supplied analysis software.
The PCA3 score was calculated as (PCA3 mRNA)/(PSA
mRNA) × 1000. Transrectal ultrasound guided biopsy with
at least 10 peripheral zone cores was performed, and the
specimens were reviewed by local pathologists.
Statistical analyses
The age, values for the PCA3 scores, PSA levels, and %
free PSA between prostate cancer patients and subjects
with BPH were compared using the Wilcoxon rank sum
test. In men with positive biopsy, the same test was used
to examine the significance of differences in marker
values from patients with Gleason scores ≤7 and with
Gleason scores ≥8. Pearson correlation coefficients ex-
amined the relationship between PCA3 score and PSA
level. Univariate associations of biopsy outcome with
base predictors age, PSA and PCA3 score were evaluated
using simple logistic regression analysis. In addition,
adjusted odds ratios (aORs) were calculated for predic-
tors that were statistically significant in the multivariate
model.
The performance of PCA3 score for detecting prostate
cancer was evaluated by sensitivity and specificity and
their associated 95 % confidence intervals (CI) at various
cutoff points using the receiver operating characteristic
(ROC) analysis. The diagnostic accuracy of the PCA3
score was compared to that of PSA using the areas
under the ROC curve (AUC) using the nonparametric
method of Delong et al. [21]. The Youden index, calcu-
lated as sensitivity + specificity-1, was used for capturing
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the maximum vertical distance of the ROC curve and
for determining cut-offs points. Statistical tests were per-
formed using SAS 9.1 software (Cary,NC, USA). All tests
were 2-tailed and P < 0.05 was considered the cut-off
level for statistical significance for all analyses.
Results
Study population
Of the 136 included patients, 112 (82.4 %) had prostate
cancer and 24 (17.6 %) were BPH on positive biopsy
(Table 1). Ages ranged from 51 to 88 years and the me-
dian age was 70 years (interquartile range, IQR 66–77).
Among the subjects with prostate cancer, the patho-
logical biopsy Gleason score was ≤7 in 67.0 % and ≥8 in
33.0 % of men.
The probability of a positive biopsy increased with
increasing PCA3 scores. The median PCA3 score was
significantly higher in men with positive biopsy (111.37,
IQR 42.64–320.90) vs BPH (17.76, IQR 9.19–81.90,
P < 0.01). However, there was no significant difference in
PCA3 scores between prostate cancer patients with biopsy
Gleason score ≤7 (113.68, IQR 49.38–326.44) and patients
with biopsy Gleason score ≥8 (102.59, IQR 12.07–278.23,
P = 0.27). There was also no significant difference in
PCA3 scores between prostate cancer patients with biopsy
Gleason score ≤6 (94.26, IQR 41.81–326.44) and patients
with biopsy Gleason score ≥7 (139.02, IQR 42.66–295.69,
P = 0.56).
The probability of a positive biopsy also increased with
increasing PSA. The median PSA was 13.67 (IQR, 7.98–
29.02), and the prostate cancer patients had a signifi-
cantly higher median PSA level (15.54, IQR 8.49–47.70)
than BPH subjects (8.70, IQR 6.39–12.17, P < 0.01). The
prostate cancer patients with Gleason score ≥8 had a
significantly higher PSA level (54.09, IQR 13.46–100.00)
than those with Gleason score ≤7 (13.21, IQR 8.43–
21.25, P < 0.01). The PSA was <4 ng/ml in 9 men
(6.6 %), 4–10 ng/ml in 37 men (27.2 %) and ≥10 ng/ml
in 90 men (66.2 %). There was no significant difference
in PCA3 scores among 3 groups of subjects with differ-
ent PSA level. No relationship was found between PCA3
score and PSA based on correlation analysis (r = 0.08,
P = 0.33).
ROC curve
A ROC curve was used to demonstrate the diagnostic
performance of PCA3 score and PSA for detecting pros-
tate cancer (Fig. 1). The figure included the sensitivity
and specificity of the two assays. The AUC of PCA3
score and PSA was 0.775 (95 % CI, 0.695–0.842) and
0.736 (95 % CI, 0.653–0.808), respectively. ROC analysis
showed that there was no significant difference in AUC
between PCA3 score vs PSA (P = 0.60).
Correlation of PCA3 score and PSA with diagnosis of
prostate cancer
Results in terms of sensitivity and specificity are shown
in Table 2. The PCA3 score cutoff of 35 provided the
optimal balance (i.e., the maximum sum of sensitivity
and specificity) between sensitivity (80.4 %) and specificity
(62.5 %). Subjects with a PCA3 score of 35 or greater had
a 6.8-fold higher probability of a positive biopsy than those
with a PCA3 score less than 35 (P < 0.01) (Table 3).
The sensitivity of PCA3 score (≥35) was 80.4 % (90/
112) (95 % CI 71.8–87.3) and the specificity was 62.5 %
(15/24) (95 % CI, 40.6–81.2). The sensitivity and speci-
ficity of PSA (≥4 ng/ml) were 95.5 % (107/112) (95 % CI
89.9–98.5) and 16.7 % (4/24) (95 % CI 4.7–37.4), re-
spectively; while the sensitivity and specificity of PSA
(≥10 ng/ml) were 71.4 % (80/112) (95 % CI 62.1–79.6)
and 58.3 % (14/24) (95 % CI 36.6–77.9). The sensitivity
Table 1 The characteristics of the study population
Prostate cancer BPHa P value
Age (Years)b 71.00 ± 11.00 67.00 ± 13.00 0.12
PSA(ng/ml)b 15.54 ± 39.21 8.70 ± 5.78 <0.01
PCA3 score 111.37 ± 278.26 17.76 ± 72.71 <0.01
<35 22 (19.6) 15 (62.5) <0.01
≥35 90 (80.4) 9 (37.5)




aBPH, benign prostatic hyperplasia
bMedian ± interquartile range
Fig. 1 ROC curve of PCA3 score and PSA for detecting prostate
cancer. PCA3: prostate cancer gene 3; PSA: prostate-specific antigen.
ROC: receiver operating characteristic
Huang et al. BMC Urology  (2015) 15:118 Page 3 of 6
for detecting prostate cancer was comparable, but the
specificity was significantly lower for PSA (≥4 ng/ml)
than PCA3 score (≥35). Although without statistical sig-
nificance, both sensitivity and specificity of PSA (≥10 ng/
ml) were lower than PCA3 score (≥35).
Univariate and multivariate logistic regression analyses
In univariate analysis, PSA >10 ng/ml (vs. <4 ng/ml) and
a PCA3 score of ≥35 were significant independent predic-
tors of positive biopsies (Table 3). In multivariate analysis,
a PCA3 score of ≥35 remained significant independent
predictor of positive biopsies (adjusted OR 6.73; 95 % CI
2.49–18.14). PSA >10 ng/ml (vs. <4 ng/ml) was also sig-
nificant (P = 0.02).
Discussion
Due to the low specificity of PSA for detecting prostate
cancer, unnecessary biopsy remains substantial [5]. The
discovery and the development of novel biomarkers for
prostate cancer diagnosis remains a challenge, despite
the widespread use of PSA and DRE. The study evalu-
ated the PCA3 assay as an additional tool in facilitating
diagnosis of prostate cancer in Chinese men. An increas-
ing PCA3 score corresponded with an increasing prob-
ability of a positive biopsy. The mean PCA3 score was
significantly higher in men with positive biopsy vs a
negative biopsy. The slight superiority of diagnostic ac-
curacy of PCA3 score over PSA level was shown in this
study, although without statistical significance. Data was
also consistent with the PCA3 score being independent
of PSA level [10, 11].
In a European multicenter study, the diagnostic accur-
acy of the PCA3 score was evaluated in men undergoing
an initial biopsy [22]. The AUC ROC for the PCA3 score
for predicting biopsy outcome was 0.761 and compar-
able to that in this study at 0.775. In European PCA3
studies, the AUC ROC was 0.761 in the initial and 0.658
in the repeat biopsy study [10]. These results suggested
that the PCA3 assay can be used to guide both initial
and repeat biopsy decisions. Therefore, PCA3 score may
be considered clinically meaningful and its application in
clinical practice can be justified [22, 23]. The PCA3
score cutoff of 35 provided the optimal balance between
sensitivity (80.4 %) and specificity (62.5 %). Subjects with
a PCA3 score of 35 or greater had a 6.8-fold higher
probability of a positive biopsy than those with a PCA3
score less than 35 (P < 0.01). However, the additive value
of PCA3 score in predicting biopsy outcome and the
most optimal PCA3 score cutoff should be further evalu-
ated by prospective studies to identify men with a high
probability of a positive biopsy.
Multiple studies have also compared the diagnostic
performance of the PCA3 assay to that of the traditional
biomarkers, such as PSA and % free PSA [10, 11, 19].
These studies have shown the superiority of the PCA3
score over PSA level, although with slight improvement
[19]. In our study, the AUC of PCA3 score and PSA was
0.775 (95 % CI, 0.695–0.842) and 0.736 (95 % CI, 0.653–
0.808), respectively; and there was no significant differ-
ence (P = 0.60). This discrepancy can be explained by the
smaller sample of men and by the restricted proportion
of negative biopsy studied in the present report (82.4 %
positive biopsy); this resulted in a decrease of statistical
power. However, the sensitivity for detecting prostate
cancer was comparable, but the specificity was signifi-
cantly lower for PSA (≥4 ng/ml) than PCA3 score (≥35);
both sensitivity and specificity of PSA (≥10 ng/ml) were
lower than PCA3 score (≥35), although without statis-
tical significance. Most importantly, data were also con-
sistent with the PCA3 score being independent of PSA
level, i.e., the diagnostic accuracy of the PCA3 score was
not affected by PSA levels, confirming the findings of
prior studies [10, 11, 22]. It was demonstrated that PCA3
fulfilled the most stringent criteria for a novel marker, i.e.,
in addition to univariate discriminatory ability it improved
sensitivity and specificity and confirmed its independent
predictor status [23].
In the analysis of the overall cohort of the European
study, Haese et al. found that the PCA3 score was
Table 2 Sensitivity and specificity of the PCA3 score and PSA
% Sensitivity (95 % CI) % Specificity (95 % CI)
PCA3 score cutoff 20 83.0 (74.8–89.5) 58.3 (36.6–77.9)
PCA3 score cutoff 35 80.4 (71.8–87.3) 62.5 (40.6–81.2)
PSA cutoff 4 95.5 (89.9–98.5) 16.7 (4.7–37.4)
PSA cutoff 10 71.4 (62.1–79.6) 58.3 (36.6–77.9)
Table 3 Univariate and multivariate logistic regression analyses
in predicting prostate cancer detection upon prostate biopsy
OR (95 % CI) P value
Univariate logistic regression model
Age 1.05 (0.99–1.11) 0.14
% free PSA 1.22 (0.75–1.98) 0.43
PSA level (ng/ml)
<4 1.0
4 ~ 10 2.16 (0.48–9.70) 0.31
>10 6.40 (1.47–27.83) 0.01
PCA3 score
<35 1.0
≥35 6.82 (2.64–17.61) <0.01
Multivariate logistic regression model
PSA level 4 ~ 10 ng/ml 2.66 (0.50–14.08) 0.25
PSA level >10 ng/ml 6.99 (1.38–35.33) 0.02
PCA3 score ≥35 6.73 (2.49–18.14) <0.01
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significantly higher in men with high Gleason scores
[10]. Studies evaluating men undergoing radical prosta-
tectomy showed an association between PCA3 score,
tumor volume and Gleason score [24]. Our findings did
not confirm this. This discrepancy can be explained by
the smaller sample of men. Men at higher risk of aggres-
sive and high Gleason score prostate cancer were stud-
ied in the present study (33.0 % patients with Gleason
score ≥8). This resulted in a decrease of statistical power.
However, other studies also questioned the relationship
between the PCA3 score and aggressive prostate cancer
[10, 11, 18, 19]. The association between PCA3 score
and aggressive prostate cancer needs further evaluation
in controlled studies to confirm the utility in selecting
men with clinically insignificant prostate cancer.
The current study was subject to several limitations.
The study population was referred to a PCA3 test for
several reasons (i.e., a high PSA level or suspicious pros-
tate cancer), therefore, those who were selected to have
a PCA3 test because of a clinical concern for prostate
cancer may differ from screening populations referred to
triage testing. These subjects in the study had a median
age of 70 years (IQR 66–77) with a relatively high PSA
level (median 13.67; IQR 7.98–29.02), which is higher
than that of a typical screening population [15]. The
subjects recruited with high clinical suspicion for pros-
tate cancer could not represent the population in China,
more unlikely to reflect the actual situation in China.
Secondly, the study sample was relatively small (espe-
cially the number of participants with negative biopsy)
to compare the clinical performance of PCA3 score and
serum PSA testing. Finally, PCA3 testing was based on
formalin-fixed, paraffin-embedded tissue blocks col-
lected before biopsy, therefore the clinical relevance was
limited. To help determine the need for biopsy decision
in screening populations, the diagnostic significance of
urinary PCA3 testing will be explored in a future study.
Conclusions
This study showed that increased PCA3 in biopsy tissue
correlated with prostate cancer and that the PCA3 assay
could aid in diagnosis of prostate cancer in a limited num-
ber of Chinese men. The probability of a positive biopsy
increased with increasing PCA3 score. In this population,
the PCA3 score had a comparable diagnostic accuracy
with PSA as there was no significant difference in ROC
AUC between PCA3 score and PSA. Most importantly,
the PCA3 assay confirmed its independent diagnosis value
and may improve the diagnosis efficacy as the PCA3 score
being independent of PSA level. However, the clinical rele-
vance was limited as PCA3 testing was based on biopsy
tissue. To help determine the prediction value in guiding
biopsy decision, the diagnostic significance of urinary
PCA3 testing should be explored in future study.
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